Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective

Frontiers in Medicine

Pingyu Chen¹  Yingdan Cao¹  Xin Guan¹  Yingcheng Wang¹  Mingjun Rui¹ 

[1] School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China;Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, China;

关键词: cost-effectiveness;    abemaciclib;    CDK4/6 inhibitors;    partitioned survival model;    breast cancer;   

DOI  :  10.3389/fmed.2021.658747

来源: Frontiers

【 授权许可】

CC BY